

Post-Merger Data Confidence: Unlocking the Full Value of Acquired ELNs

Preserve Access, Integrity, and Usability of Scientific Data Post-M&A

Effective data management is essential in the competitive landscape of pharmaceutical and biotech mergers and acquisitions (M&A). Data assets, especially those stored in Electronic Lab Notebooks (ELNs), are critical to ensuring continuity, compliance, and value realization. SciY offers an advanced ELN archiving and migration solution that ensures long-term accessibility and compliance, helping organizations protect their data assets and maximize post-merger value.

Navigating M&A Challenges with SciY's ELN Archiving Solution


SciY's solution is tailored to address key obstacles that arise during M&A processes:

- Support Regulatory Compliance. Help organizations meet FDA, EMA, and other regulatory requirements by preserving ELN data in structured, auditable formats.
- Protect Intellectual Property (IP). Safeguard critical IP including experimental data, formulations, and clinical results from loss or mismanagement.
- Preserve Institutional Knowledge. Retain the historical scientific insights stored in ELNs by following FAIR data principles, even amid personnel or system changes.
- Maintain Data Integrity and Quality. Apply digital preservation best practices to ensure data authenticity, traceability, and long-term usability.



Benefits of Migrating ELN Data with SciY

SciY's approach to data migration and archiving ensures business continuity and minimizes risks to data integrity and accessibility during M&A:



Secure Your Scientific Knowledge Today

SciY helps you protect your essential scientific knowledge, ensure compliance, and unlock long-term value from your data assets.

Visit our website to learn more. http://www.sciy.com

Answering the Scientific Why.



